Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of GLP-1 on Microvascular Insulin Responses in T1DM
NCT04133922Phase 1Withdrawn
- Sponsor
- University of Virginia
- Start
- Oct 2019
- Primary completion
- Oct 2023
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1 trial of Glucagon-like peptide 1 in type 1 diabetes mellitus (T1D) (3 arms), sponsored by University of Virginia. Primary endpoints: Change in microvascular blood volume at 2 hours and Change in insulin sensitivity at 2 hours. Planned start Oct 2019; status: withdrawn.
02
Drugs
Glucagon-like peptide 1
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT04133922.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04133922.